Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1089769 | 0.73 | — | — | |
| SCHEMBL1177125 | 0.70 | CRBN (0.43) | — | |
| SCHEMBL14867426 | 0.70 | HCAR2 (0.35) | HCAR2 | |
| SCHEMBL1047817 | 0.69 | MAPT (0.41) | NOS3NOS1NOS2HCAR2 | |
| SCHEMBL16253822 | 0.68 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL14867427 | 0.67 | KDM4E (0.35) | HCAR2 | |
| SCHEMBL19419764 | 0.67 | TLR4 (0.39) | NOS3NOS1NOS2 | |
| SCHEMBL20608621 | 0.67 | CA1 (0.38) | NOS3NOS1NOS2 | |
| SCHEMBL812088 | 0.67 | CA1 (0.38) | NOS3NOS1NOS2 | |
| Water SCHEMBL8470623 | 0.67 | MAPT (0.39) | NOS3NOS1NOS2HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881827-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-09-28 | — | — | EP | disclosed |
| US-7888344-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2011-02-15 | — | — | US | disclosed |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2008-12-11 | — | — | US | disclosed |
| EP-1881827-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006114606-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | MAP4K2, PDPK1, DAPK2 | NOS3 2419/4885NOS1 2767/4885NOS2 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.